JHS Sven.Lab.

Which are the latest news on JHS Sven.Lab.?

Why is JHS Svendgaard Laboratories Ltd falling/rising?

As of 08-Aug, JHS Svendgaard Laboratories Ltd's stock price is currently at 7.86, reflecting a 3.15% increase today, outperforming its sector. However, it has a year-to-date decline of 20.28% and shows mixed signals regarding its longer-term trend.

As of 08-Aug, JHS Svendgaard Laboratories Ltd's stock price is rising, currently at 7.86, with a change of 0.24, reflecting an increase of 3.15%. This rise is notable as the stock has outperformed its sector by 4.55% today. Additionally, over the past week, the stock has shown a positive return of 3.69%, significantly higher than the Sensex's increase of 0.52% during the same period. <BR><BR>However, it is important to note that despite the recent uptick, the stock has experienced substantial declines over longer periods, with a year-to-date decrease of 20.28% and a one-year decline of 27.22%. The stock's performance is also characterized by lower investor participation, as indicated by a delivery volume that has fallen by 77.53% compared to the five-day average. <BR><BR>In terms of moving averages, the current price is higher than the 5-day, 20-day, and 50-day moving averages, but it remains below the 100-day and 200-day moving averages, suggesting mixed signals regarding its longer-term trend. Overall, while the stock is currently rising, its longer-term performance indicates significant challenges.

How big is JHS Sven.Lab.?

As of 10th June, JHS Svendgaard Laboratories Ltd has a market capitalization of 69.00 Cr and reported net sales of 101.70 Cr with a net loss of 1.92 Cr over the latest four quarters. Shareholder's funds are valued at 172.73 Cr, with total assets of 197.87 Cr.

As of 10th June, <BR><BR>Market Cap: JHS Svendgaard Laboratories Ltd has a market capitalization of 69.00 Cr, classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 101.70 Cr, while the sum of Net Profit for the same period shows a loss of 1.92 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the latest annual data is March 2025. Shareholder's Funds are valued at 172.73 Cr, and Total Assets amount to 197.87 Cr.

Who are in the management team of JHS Sven.Lab.?

The management team of JHS Sven.Lab includes Nikhil Nanda (Managing Director), Rajagopal Chakravarthi (Chairman & Independent Director), and several Independent Directors: Mukul Pathak, Rohina Sanjay Sangtani, Kapil Minocha, and Sunil Arora, along with Additional Directors Vinay Mittal and Upma Chawdhry, and Komal as Company Secretary & Compliance Officer.

The management team of JHS Sven.Lab. includes the following individuals:<BR><BR>1. **Nikhil Nanda** - Managing Director<BR>2. **Mukul Pathak** - Independent Director<BR>3. **Rohina Sanjay Sangtani** - Independent Director<BR>4. **Rajagopal Chakravarthi** - Chairman & Independent Director<BR>5. **Kapil Minocha** - Independent Director<BR>6. **Sunil Arora** - Additional Independent Director<BR>7. **Vinay Mittal** - Additional Director<BR>8. **Komal** - Company Secretary & Compliance Officer<BR>9. **Upma Chawdhry** - Additional Director<BR><BR>If you need more information about any specific member or their roles, feel free to ask!

Who are the peers of the JHS Sven.Lab.?

JHS Sven.Lab.'s peers include Virat Crane Inds, Simran Farms, Terai Tea Co, IEL, Nakoda Group, Kothari Ferment., Oceanic Foods, Yuvraaj Hygiene, and Ceeta Industries. IEL has the highest 1-year return at 16.49%, while JHS Sven.Lab. has a return of -40.21%.

Peers: The peers of JHS Sven.Lab. are Virat Crane Inds, Simran Farms, Terai Tea Co, IEL, Nakoda Group, Kothari Ferment., Oceanic Foods, Yuvraaj Hygiene, and Ceeta Industries.<BR><BR>Quality Snapshot: Excellent management risk is observed at Virat Crane Inds, while Average management risk is found at IEL and Oceanic Foods, and the rest have Below Average management risk. Growth is Excellent at Omfurn India, Average at Yuvraaj Hygiene, and the rest have Below Average growth. Capital Structure is Excellent at Virat Crane Inds, Average at IEL and Oceanic Foods, and the rest have Below Average capital structure.<BR><BR>Return Snapshot: The peer with the highest 1-year return is IEL at 16.49%, while the lowest is Terai Tea Co at -42.03%. JHS Sven.Lab.'s 1-year return is -40.21%, which is higher than Terai Tea Co but lower than IEL. Additionally, peers with negative six-month returns include JHS Sven.Lab., Terai Tea Co, Oceanic Foods, and Kothari Ferment.

What does JHS Sven.Lab. do?

JHS Svendgaard Laboratories Ltd is a micro-cap company that manufactures oral care products within the FMCG industry. As of March 2026, it reported net sales of 33 Cr and a net loss of 4 Cr, with a market cap of INR 69 Cr.

Overview:<BR>JHS Svendgaard Laboratories Ltd manufactures a comprehensive range of oral care products and operates within the FMCG industry, classified as a micro-cap company.<BR><BR>History:<BR>The company was incorporated in an unspecified year and has not reported any status changes. The latest quarterly results available are for March 2026, showing net sales and profit figures.<BR><BR>Financial Snapshot:<BR>Net Sales: 33 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: -4 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 69 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: N/A <BR>Industry P/E: 45 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.02 <BR>Return on Equity: -1.10% <BR>Price to Book: 0.40<BR><BR>Contact Details:<BR>Address: Trilokpur Road Kheri(Kala Amb), Tehsil Nahan District Sirmour Himachal Pradesh : 173030 <BR>Tel: 91-9218-400346 <BR>Email: cs@svendgaard.com <BR>Website: http://www.svendgaard.com

Are JHS Svendgaard Laboratories Ltd latest results good or bad?

The latest results for JHS Svendgaard Laboratories Ltd are concerning, as the company reported a significant revenue increase of 40.52% in Q4 FY26 but also a net loss of ₹3.57 crores, reflecting ongoing operational inefficiencies and raising doubts about its long-term viability.

The latest results for JHS Svendgaard Laboratories Ltd indicate a challenging situation for the company. While the revenue for Q4 FY26 saw a significant increase, reaching ₹32.70 crores—up 40.52% from the previous quarter and 29.92% year-on-year—the company reported a net loss of ₹3.57 crores. This marks a drastic decline of 551.90% compared to the previous quarter, where the company had a modest profit.<BR><BR>Moreover, the operating margin is negative at -4.95%, although it has improved from -21.37% in the same quarter last year. The profit after tax (PAT) margin also remains negative at -10.92%, albeit better than the previous year's -27.65%.<BR><BR>Overall, the results reflect a troubling contradiction: strong revenue growth is not translating into profitability, highlighting ongoing operational inefficiencies. The company has reported losses in five out of the last seven quarters, raising concerns about its long-term viability and ability to generate sustainable returns for shareholders. Given these factors, the latest results can be characterized as bad, indicating significant challenges ahead for JHS Svendgaard.

Should I buy, sell or hold JHS Svendgaard Laboratories Ltd?

When is the next results date for JHS Svendgaard Laboratories Ltd?

The next results date for JHS Svendgaard Laboratories Ltd is 26 May 2026.

The next results date for JHS Svendgaard Laboratories Ltd is scheduled for 26 May 2026.

How has been the historical performance of JHS Sven.Lab.?

JHS Sven.Lab. has faced significant financial challenges, with fluctuating net sales and increasing losses, reporting a profit after tax of -19.74 Cr in March 2025 and negative cash flow from operating activities of -5.00 Cr. Total liabilities matched total assets at 197.87 Cr, indicating a difficult financial position.

Answer:<BR>The historical performance of JHS Sven.Lab. shows a fluctuating trend in net sales and profitability over the years, with significant losses in recent periods.<BR><BR>Breakdown:<BR>JHS Sven.Lab. reported net sales of 92.00 Cr in March 2025, an increase from 70.80 Cr in March 2024, but a decline from 96.21 Cr in March 2023. The total operating income mirrored this trend, reaching 92.00 Cr in March 2025, while total expenditure rose to 96.01 Cr, leading to an operating profit (PBDIT) of -1.13 Cr for the same period. This marked a deterioration from the previous year's operating profit of 3.38 Cr. The company faced a profit before tax of -12.51 Cr in March 2025, worsening from -3.43 Cr in March 2024, and a profit after tax of -19.74 Cr, compared to -4.06 Cr in the prior year. The earnings per share also reflected this decline, showing -2.31 in March 2025. On the balance sheet, total liabilities increased to 197.87 Cr in March 2025, while total assets were reported at 197.87 Cr, indicating a challenging financial position. Cash flow from operating activities was negative at -5.00 Cr, contributing to a net cash outflow of -2.00 Cr for the year. Overall, JHS Sven.Lab. has experienced significant financial challenges, particularly in profitability and cash flow, over the recent years.

Who are the top shareholders of the JHS Sven.Lab.?

The top shareholders of JHS Sven.Lab. include Nikhil Nanda with 30.95%, individual investors with 46.91%, and Vijay Mohan Govila as the highest public shareholder at 2.8%. Additionally, four foreign institutional investors hold a combined 1.6%, while mutual funds hold no shares.

The top shareholders of JHS Sven.Lab. include Nikhil Nanda, who is the promoter with the highest holding at 30.95%. Individual investors collectively hold 46.91% of the shares. Additionally, Vijay Mohan Govila is noted as the highest public shareholder with a stake of 2.8%. The company also has 4 foreign institutional investors (FIIs) holding a combined 1.6% of the shares, while mutual funds do not hold any shares in this company.

Is JHS Sven.Lab. overvalued or undervalued?

As of March 31, 2023, JHS Sven.Lab. is rated as risky and appears undervalued with a PE ratio of -6.59 and a year-to-date return of -37.5%, indicating significant financial distress compared to its peers like Hindustan Unilever and Nestle India.

As of 31 March 2023, the valuation grade for JHS Sven.Lab. moved from does not qualify to risky. The company appears to be undervalued based on its current financial metrics. Key ratios include a PE ratio of -6.59, an EV to EBITDA of -24.39, and a Price to Book Value of 0.64, indicating significant financial distress compared to its peers.<BR><BR>In comparison to its industry peers, JHS Sven.Lab. shows stark contrasts, particularly when compared to Hindustan Unilever with a PE ratio of 53.88 and Nestle India at 75.2, both categorized as very expensive. The company's recent stock performance has been challenging, with a year-to-date return of -37.5%, contrasting sharply with the Sensex's 6.20% gain during the same period. This suggests that while the stock may be undervalued, it faces significant operational challenges that investors should consider.

What is the technical trend for JHS Sven.Lab.?

As of May 30, 2025, JHS Sven.Lab. exhibits a bearish trend with moderate strength, supported by bearish indicators across multiple time frames, despite some mixed signals in momentum.

As of 30 May 2025, the technical trend for JHS Sven.Lab. has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. The weekly MACD is mildly bullish, but the monthly MACD is bearish, indicating a divergence in momentum. Both the weekly and monthly Bollinger Bands are bearish, reinforcing the downward pressure. Daily moving averages are also bearish, suggesting short-term weakness. The KST shows a mildly bullish signal on the weekly but is bearish on the monthly, while the Dow Theory indicates a mildly bearish trend on the weekly and mildly bullish on the monthly, reflecting mixed signals. Overall, the OBV is mildly bearish on both time frames, contributing to the bearish outlook.

Has JHS Sven.Lab. declared dividend?

Yes, JHS Svendgaard Laboratories Ltd has declared an 8% dividend, amounting to 0.80 per share, with an ex-date of December 26, 2011. However, the company has experienced significant declines in total returns over multiple periods, with the most recent five-year period showing only a slight positive return of 1.1%.

Yes, JHS Svendgaard Laboratories Ltd has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 8%<BR>- Amount per share: 0.80<BR>- Ex-date: 26 Dec 11<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -46.21%, the dividend return was 0%, resulting in a total return of -46.21%.<BR><BR>For the 1-year period, the price return was -36.81%, the dividend return was 0%, leading to a total return of -36.81%.<BR><BR>Over the 2-year period, the price return was -23.29%, the dividend return was 0%, which resulted in a total return of -23.29%.<BR><BR>In the 3-year period, the price return was -48.05%, the dividend return was 0%, culminating in a total return of -48.05%.<BR><BR>During the 4-year period, the price return was -40.37%, the dividend return was 0%, giving a total return of -40.37%.<BR><BR>For the 5-year period, the price return was 1.1%, the dividend return was 0%, resulting in a total return of 1.1%.<BR><BR>Overall, while JHS Svendgaard Laboratories Ltd declared a dividend in the past, the recent total returns indicate significant declines over multiple periods, with the most recent five-year period showing only a slight positive return. The lack of recent dividends suggests a challenging financial environment for the company.